Infertility treatment is complex.
We’re here to make it clearer.
A BIOTECHNOLOGY
PARTNER IN
REPRODUCTIVE
HEALTH
Celmatix is developing diagnostic tools to improve reproductive health outcomes for female infertility.
By partnering with fertility clinics and other stakeholders, we are making better use of electronic medical data.
Our offerings help physicians interpret data, clarify causes of failure and optimize treatment strategies to improve success rates.
Today clinicians consider a range of options before beginning treatment without knowing the genetic and phenotypic indicators underlying risk factors. With early access to better prognostics, physicians can more easily identify optimal treatment strategies.
68%
of IVF treatment cycles in women under 40 do not result in a live birth – SART 2009
INTRODUCING A
NON-INVASIVE DIAGNOSTIC
Our innovative, non-invasive test will assess the genetic indicators underlying egg quality and female infertility.
This will allow reproductive specialists to diagnose genetic cases of infertility at the beginning of the treatment process.
By using genetic biomarkers to assess potential problems, physicians can develop optimal treatment paths, plan for egg preservation and pre-screen prospective egg donors.
A STREAMLINED USE CASE
This diagnostic product is in development and not yet available to the public. It may yield results that narrow treatment alternatives to a greater or lesser degree. The test itself will neither improve nor diminishes patients’ chances of becoming pregnant.
DRIVING INNOVATION
WITH DATA ANALYTICS
Celmatix mines a large set of de-identified electronic medical records from IVF and other fertility treatment cycles.
By applying advanced data analytics and machine learning methods, we provide clinical partners with actionable analysis of the markers of success and failure in their patient populations.
Our data reports clarify questions that are critical to improving success rates—questions that affect outcomes across variables, including AMH levels, age and embryo quality. They also show clinics how their methods compare to others and promote “best practices” for infertility treatment.
A CLINIC WITH ACTIONABLE INFORMATION
“Everyone’s tracking data, Celmatix is taking it to the next level.”
HOW CELMATIX HELPS OPTIMIZE TREATMENT DECISIONS
Currently, fertility specialists and patients navigate treatment options with little personalized data. This can be complex, frustrating and involve multiple failed cycles. Celmatix offerings streamline the process, making treatment decisions clearer, more efficient and less stressful.
GAME-CHANGING PARTNERSHIPS
Celmatix is partnering with various stakeholders to streamline decisions around infertility treatment.
Our diagnostic and analytical tools offer clinics flexible capabilities across treatment categories, helping to:
- Identify genetic biomarkers to enable optimized treatment paths
- Clarify questions affecting outcomes across variables critical to success rates
- Provide actionable analysis about indicators underlying success and failure in patient populations
- Evaluate internal capabilities, identify doctors who may need mentoring or whose patient load is uneven
- Allow comparisons between clinical methods and optimize financial return.
Our data analytics enable payers to:
- Reduce costs by eliminating unsuccessful treatments
- More efficiently use population data to define eligibility coverage
- Interpret retrospective claims and EMR data analysis
- Assess patterns in diagnosis and prescription
- Clarify the causes of treatment cycle failure
- Analyze efficiency at the level of doctors, clinics and cost per patient
Our data analytics allow pharmaceutical companies to better understand:
- Cost effectiveness of different practice patterns, treatments and brands
- Physician treatment choices and related outcomes
- Reimbursement amounts, denials and outcomes by payer type and plan
- Comparative persistency, compliance and related costs/outcomes
- Longitudinal patient-level data to inform sales and marketing, R&D and clinical trials and market and outcomes research
AN OPPORTUNITY TO STREAMLINE TREATMENT
Celmatix’s non-invasive method for assessing the genetic and phenotypic indicators underlying egg quality and female infertility has significant potential both in the recapture and current treatment markets. Viable eggs are needed to succeed, and millions of women would benefit from knowing more about their potential to produce quality eggs.
Globally, 56% of assisted reproductive technology (ART) procedures are performed in Europe. In addition to the large European market, roughly 60 million couples in China and India are currently seeking infertility treatment.
Our data and diagnostic offerings will streamline infertility diagnosis and treatment. Both have significant potential in the recapture market and among women who have already chosen to seek treatment.
Approximately 7.3 million American women are infertile. About 40% pursue treatment, (142,000 IVF procedures in 2007), while the other 60% avoid what they fear will be an expensive and emotionally taxing process.
our mission
Celmatix is committed to streamlining the diagnosis and treatment of female infertility.
We’re building partnerships to make better use of electronic data and empowering clinicians with actionable personalized information. By making treatment decisions clearer, we aim to make the infertility process more efficient, more effective and less emotionally taxing.
our team
Laura Towart Bandak, MSc
founder, chief executive officer
Ms. Bandak holds an MSc degree in Neuroscience from Cornell University (Weill Medical College/Sloan Kettering Institute, NYC). Her thesis work on the molecular pharmacology of the mu opioid receptor was published in the field of gonadal hormones. She also has extensive exposure to the biotechnology sector as an independent consultant. Ms. Bandak graduated cum laude from George Washington University, Washington DC, with a BA Honors in English and a BS in Biology.
Piraye Yurttas Beim, PhD
founder, chief scientific officer
Dr. Beim is one of a handful of experts in the genetics of female fertility. Her postdoctoral work (Gurdon Institute, University of Cambridge, England) is in mammalian pre-implantation embryology and her doctoral work (Cornell University, Weill Medical College/Sloan Kettering Institute, NYC) focused on the molecular and genetic underpinnings of mammalian infertility. Dr. Beim holds a BA in HonorsPlan II, an elite multidisciplinary honors program, and a BS in Biology from the University of Texas at Austin.
our growing team
Sofia Akber, PhD
data analyst
Dr. Akber brings years of experience in computational modeling. She has worked for a number of start up companies and before the private sector, held an Assistant Professorship in Geophysics at the University of California, San Diego (Scripps Institution of Oceanography). She holds a BS with Honors in Electrical Engineering from the California Institute of Technology.
Pavithra Shivakumar, PhD
bioinformatics associate
Dr. Shivakumar holds a PhD from Yale University in Computational Biology and Bioinformatics. Her thesis work focused on structural assessment of compounds and pharmacogenomic profiling in cancer. She has a BS with highest honors in Computer science and honors in Biology from Rutgers University.
Steve Winick
director
Mr. Winick is a partner of Topspin Partners, a lead investors in Celmatix. He came to Topspin from Honeywell, Intl., where he most recently served as CIO of its $2 billion Security Group. Mr. Winick received a BS in Economics from the Wharton School of the University of Pennsylvania and a BS in Electrical Engineering, also from University of Pennsylvania.
our advisors
corporate
Cory Ondrejka
director of engineering, facebook
Mr. Ondrejka’s experience spans several fields from defense contracting to video game development. He co-founded Walletin, which was acquired by Facebook, and Linden Lab, the creator of Second Life. He served as Executive Vice President for Global Digital Marketing at EMI Music and was a visiting professor at the Annenberg School for Communication at the University of Southern California.
Christina Carlisle Jones
founder & chief executive officer, extend fertility, inc.
Ms. Jones co-founded Trilogy Software and has served as President and Founder of pcOrder. Ms. Jones is an Aspen Institute Henry Crown Fellow and served on the Board of Directors of Fertile Hope, before it was acquired by the Lance Armstrong Foundation. She received a BA in Economics from Stanford University and an MBA from Harvard Business School.
our advisors
scientific
Roger Gosden, PhD, DSc
professor and director of research in reproductive biology, weill medical college of cornell university, new york, ny (retired)
Dr. Gosden received his research training in Cambridge under the physiologist Robert Edwards who, with the gynecologist Patrick Steptoe, achieved the world’s first successful in vitro fertilization (IVF) pregnancy. Dr. Gosden has remained an active member of the global reproductive biology community through publications and conference lectures.
Alan Copperman, MD
director of infertility & vice chairman of obstetrics and gynecology, mount sinai medical center; co-founder & co-director. rma of new york
Dr. Copperman is a widely respected Reproductive Endocrinologist. He has published award-winning papers on egg freezing, infertility and IVF. Dr. Copperman has received awards from patient advocacy groups including The American Fertility Association and Resolve. He currently serves on the Fertility Advisory Committee to LIVESTRONG.
James Hicks, PhD
research professor & director of women’s cancer genomics initiative, cold spring harbor laboratory
Dr. Hicks is a leading expert on the role of chromosomal deletions and duplications in cancer and autism. His current research involves applying genome-wide microarray strategies to identify diagnostic and prognostic markers in autism spectrum disorders as well as breast, ovarian and cervical cancer.
MEDIA & RESOURCES
News Releases
Feb. 27, 2011
Celmatix Completes Series A Financing
Celmatix Inc., an emerging biotechnology company focused on reproductive medicine, announced today the closing of a Series A financing round led by Topspin Partners. This follows initial funding through seed investment and government grants… READ MORE
MEDIA CONTACT
Laura Towart Bandak, M.Sc.
Co-founder & Chief Executive Officer
12 Desbrosses Street
New York, NY 10013
info@celmatix.com
+1.646.389.0245
CONTACT US
Contact us for more information about Celmatix:
• Our Mission
• Products & Services
• Careers
• Investment
• Our Mission
• Products & Services
• Careers
• Investment
CELMATIX, INC.
Laura Towart Bandak, M.Sc.
Co-founder & Chief Executive Officer
12 Desbrosses Street
New York, NY 10013
info@celmatix.com
+1.646.389.0245